• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
GU Junjie.Clinical observation on multipurpose Anziheji in treatment of endometriosis associated infertility of cold stagnation and blood stasis type[J].Journal Of Pharmaceutical Research,2017,36(9):551-554[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3814times   Download 2933次 QR Code for this article
Scan with your phone!
安子合剂一方多用治疗寒凝血瘀型子宫内膜异位症不孕患者的临床观察
顾俊杰
Font:Larger+|Default|Smaller-
(南京中医药大学第一附属医院,江苏 南京 210029)
摘要:
目的 观察安子合剂一方多用治疗寒凝血瘀型子宫内膜异位症(EMs)不孕患者的疗效。方法 60例患者随机分成对照组(20例)和治疗组(40例)。对照组采用口服散结镇痛胶囊,每次4粒,每天3次;治疗组采用安子合剂一方多用治疗,每天服药2次,治疗周期为12个月。检测治疗前后血清癌抗原125(CA125)、癌抗原199(CA199)水平;检测治疗前后血清基质金属蛋白酶-3(MMP-3)、基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)和肿瘤坏死因子-α(TNF-α)水平;观察治疗组患者的排卵情况。结果 治疗后治疗组主要症状、体征评分、癌抗原125和癌抗原199水平均显著低于对照组(P<0.05);治疗后对照组血清炎症因子基质金属蛋白酶-3、基质金属蛋白酶-9、血管内皮生长因子、肿瘤坏死因子-α水平明显低于对照组(P<0.05);治疗组减轻痛经疼痛临床疗效总有效率高于对照组(P<0.05)。治疗组患者的卵泡发育情况明显改善(P<0.05),且以安子合剂联合其改良方服药患者的卵泡发育情况优于安子合剂单用患者的卵泡发育情况(P<0.05),安子合剂联合其改良方治疗不孕临床疗效总有效率90%优于安子合剂单用的治疗总有效率65%(P<0.05)。结论 安子合剂一方多用能显著改善EMs患者疼痛,减低炎症反应,提高患者生活质量,同时改善患者卵巢功能,提高治疗不孕有效率。
关键词:  子宫内膜异位症  不孕症  安子合剂  一方多用  疼痛  卵巢功能
DOI:10.13506/j.cnki.jpr.2017.09.015
基金项目:
Clinical observation on multipurpose Anziheji in treatment of endometriosis associated infertility of cold stagnation and blood stasis type
GU Junjie
(Affiliated Hospital of Nanjing University of TCM,Nanjing 210029,China)
Abstract:
Objective To observe the effect of multipurpose Anziheji on endometriosis(EMs) associated infertility of cold stagnation and blood stasis syndrome.Methods 60 patients were randomly divided into control group(20 cases) and observation group(40 cases).Patients in control group took Sanjie Zhentong capsule,once 4 capsules,3 times a day,and patients in treatment group took multipurpose Anziheji, 2 times a day,continuing for 12 months.The levels of serum cancer antigen 125(CA125) and CA199,levels of serum matrix metalloproteinase(MMP-3),MMP-9,vascular endothelial growth factor(VEGF) and tumor necrosis factor-α(TNF-α) were detected before and after treatment,and the symptom scores were observed.Results After therapy,scores of visual analogue scale(VAS),dysmenorrheal,pelvic pain,pelvic tenderness,and sacral ligament tenderness nodules in observation group were significantly lower than those in control group(P<0.05).After treatment,levels of CA125 and CA199 in observation group were lower than those in control group(P<0.05),levels of serum MMP-3,MMP-9,VEGF and TNF-α in treatment group were less than those in control group(P<0.05).The total effective rate in treatment group was superior to that in control group(P<0.05).The ovarian follicular development in treatment group was obviously improved(P<0.05),and the ovarian follicular development of multipurpose Anziheji treatment group was better than that of Anziheji treatment group(P<0.05).Conclusion Multipurpose Anziheji can obviously improve pain for EMs patients,reduce the inflammatory response,enhance their quality of life,improve the ovarian function of patients,and improve the efficiency of the treatment of infertility.
Key words:  Endometriosis  Infertility  Anziheji  Multipurpose  Pain  Ovarian function
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.